Tuberculosis drug development
4 European H2020 organizations list this as part of their work — 4 as their primary capability.
Most active in this area
- GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL
GSK's Spanish R&D arm specializing in tuberculosis and antimicrobial resistance drug development, from preclinical discovery through clinical trials.
“Central to anTBiotic (coordinator), TRIC-TB (ethionamide boosting), ERA4TB (pan-TB regimen), and UNITE4TB (innovative trial platform) — spanning the full pipeline from preclinical to clinical trials.”
PrimaryES7 projects - BIOVERSYS AG
Swiss biotech developing small-molecule transcriptional modulators to combat tuberculosis and drug-resistant bacterial infections, with Phase II clinical assets.
“Coordinated TRIC-TB (€6.9M) on ethionamide boosting for TB, and participated in RespiriNTM targeting mycobacterial infections.”
PrimarySMECH3 projects - GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT NON PROFIT ORGANISATION
US nonprofit accelerating tuberculosis drug development through innovative clinical trials, preclinical pipelines, and AI-driven regimen design within European consortia.
“Core mission across all three H2020 projects: EU-PEARL, ERA4TB, and UNITE4TB all address TB treatment pipelines.”
PrimaryUS3 projects - OTSUKA NOVEL PRODUCTS GMBH
Munich-based pharma R&D entity bringing drug pipeline assets and clinical pharmacology expertise into EU platform trials for tuberculosis, CNS, and metabolic diseases.
“UNITE4TB (2021-2028) is a dedicated academia-industry TB drug development program where Otsuka contributes new chemical entities and clinical pharmacology expertise.”
PrimaryDE2 projects